newsfilter
← Latest News
GlobeNewswire·

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet